IncobotulinumtoxinA versus onabotulinumtoxinA in the treatment of glabellar facial lines: Results from a multicenter, randomized, double-blinded trial - 21/04/16
Michael Kane, MD, Manhattan Eye, Ear & Throat Hospital, New York, NY, United States; Michael Gold, MD, Tennessee Clinical Research Center, Nashville, TN, United States; William Coleman, MD, Tulane Health Sciences Center, Tulane University, New Orleans, LA, United States; Derek Jones, MD, Skin Care and Laser Physicians of Beverly Hills, Beverly Hills, CA, United States; Emil Tanghetti, MD, Center for Dermatology and Laser Surgery, Sacramento, CA, United States; Tina Alster, MD, Washington Institute of Dermatologic Laser Surgery, Washington, DC, United States; Tom Rohrer, MD, Skin Care Physicians, Chestnut Hill, MA, United States; Cheryl Burgess, MD, Center for Dermatology and Dermatologic Surgery, Sacramento, CA, United States; Ava Shamban, MD, University of California Los Angeles, Los Angeles, CA, United States
Le texte complet de cet article est disponible en PDF.| Supported 100% by Merz North America, Inc. |
Vol 74 - N° 5S1
P. AB19 - mai 2016 Retour au numéro
Article précédent
- Improvement in aging appearance, social confidence, and psychological well-being with combined facial aesthetic treatment comprising onabotulinumtoxinA, dermal fillers, and bimatoprost: HARMONY study outcomes
- Independent photographic evaluation of small particle, hyaluronic acid gel plus lidocaine (SPHAL) on lip smoothness when performing lip augment
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?